Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type
Open Access
- 29 August 2013
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 32 (1) , 59
Abstract
Background: To date, no prognostic microRNAs (miRNAs) for isocitrate dehydrogenase 1 (IDH1) wild-type glioblastoma multiformes (GBM) have been reported. The aim of the present study was to identify a miRNA signature of prognostic value for IDH1 wild-type GBM patients using miRNA expression dataset from the The Cancer Genome Atlas (TCGA). Methods: Differential expression profiling analysis of miRNAs was performed on samples from 187 GBM patients, comprising 17 mutant-type IDH1 and 170 wild-type IDH1 samples. Results: A 23-micoRNA signature which was specific to the IDH1 mutation was revealed. Survival data was available for 140 of the GBM patients with wild-type IDH1. Using these data, the samples were characterized as high-risk or low-risk group according to the ranked protective scores for each of the 23 miRNAs in the 23-miRNA signature. Then, the 23 IDH1 mutation-specific miRNAs were classified as risky group and protective group miRNAs based on the significance analysis of microarrays d-score (SAM d-value) (positive value or negative value). The risky group miRNAs were found to be expressed more in the high-risk samples while the protective group miRNAs were expressed more in the low-risk samples. Patients with high protective scores had longer survival times than those with low protective scores. Conclusion: These findings show that IDH1 mutation-specific miRNA signature is a marker for favorable prognosis in primary GBM patients with the IDH1 wild type.Keywords
This publication has 24 references indexed in Scilit:
- MicroRNA-365 regulates NKX2-1, a key mediator of lung cancerCancer Letters, 2013
- Downregulation of cell‐free miR‐198 as a diagnostic biomarker for lung adenocarcinoma‐associated malignant pleural effusionInternational Journal of Cancer, 2013
- MiRly regulating metabolismBlood, 2012
- Whole‐genome microRNA expression profiling identifies a 5‐microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiformeCancer, 2012
- Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinomaInternational Journal of Cancer, 2012
- VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1α/VEGF and β-catenin/Tcf-4 signalingNeuro-Oncology, 2012
- Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemiaLeukemia, 2012
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- miRNAs in cancer: approaches, aetiology, diagnostics and therapyHuman Molecular Genetics, 2007
- Expression profiling identifies microRNA signature in pancreatic cancerInternational Journal of Cancer, 2006